Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Publications (10 of 89) Show all publications
Olsson, E., Lindman, H., Digkas, E., Thurfjell, V., Ali, H. M., Kruger, U., . . . Valachis, A. (2025). Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting. The Breast, 79, Article ID 103874.
Open this publication in new window or tab >>Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
Show others...
2025 (English)In: The Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 79, article id 103874Article in journal (Refereed) Published
Abstract [en]

Purpose: We aimed to characterize genomic alterations with potential prognostic or predictive significance in patients with metastatic triple-negative breast cancer (mTNBC) treated with chemotherapy in a real-world setting. Patients and methods: Next-generation sequencing with FoundationOne (R) CDx was conducted primarily on primary tumor tissue from 112 consecutive patients with mTNBC. Genomic alterations were subdivided into canonical oncogenic pathways and noted for their involvement in homologous recombination deficiency (HRD). Altered genes and pathways were correlated with overall survival (OS) and evaluated regarding their association with real-world progression-free survival (rwPFS) in patients treated with different chemotherapy agents. Occurrence of alterations were compared between patients with exceptional response and rapid progression to chemotherapy. Results: After exclusion due to insufficient tumor tissue or clinical data, material from 97 patients was analyzed. The most frequently altered genes were TP53 (82 %), RAD21 (25 %) and PIK3CA (23 %). Altogether, 26 % of patients had an alteration leading to HRD. None of the analyzed alterations were associated with OS. Variants leading to HRD were associated with a prolonged rwPFS in patients treated with platinum-based chemotherapy in the first line setting (hazard ratio [HR], 0.31 [95 % CI: 0.12-0.84]). Exceptional responders more often exhibited alterations in the MYC and RAS/RTK pathways compared to rapid progressors. Conclusions: Patients with tumor alterations in HRD-related genes seem to define subgroups that respond favorably to platinum-based chemotherapy. Further research into the genomic landscape of tumors from patients with rapid progression or exceptional response to different treatment strategies can provide insights into mechanisms of resistance and identify predictive biomarkers.

Place, publisher, year, edition, pages
Elsevier, 2025
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-556836 (URN)10.1016/j.breast.2025.103874 (DOI)001427504700001 ()39778370 (PubMedID)2-s2.0-85214103461 (Scopus ID)
Available from: 2025-05-28 Created: 2025-05-28 Last updated: 2025-06-17Bibliographically approved
Kjallquist, U., Tsiknakis, N., Acs, B., Margolin, S., Kessler, L. E., Levy, S., . . . Matikas, A. (2025). Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study. The Breast, 82, Article ID 104489.
Open this publication in new window or tab >>Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
Show others...
2025 (English)In: The Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 82, article id 104489Article in journal (Refereed) Published
Abstract [en]

Purpose: Gene expression profiles are used for decision making in the adjuvant setting in hormone receptorpositive, HER2-negative (HR+/HER2-) breast cancer. While algorithms to optimize testing exist for RS/Oncotype Dx, no such efforts have focused on ROR/Prosigna. This study aims to enhance pre-selection of patients for testing using machine learning. Methods: We included 348 postmenopausal women with resected HR+/HER2-node-negative breast cancer tested with ROR/Prosigna across four Swedish regions. We developed a machine learning model using simple prognostic factors (size, progesterone receptor expression, grade, and Ki67) to predict ROR/Prosigna output and compared the performance regarding over- and undertreatment with commonly employed risk stratification schemes. Results: Previous classifications resulted in significant undertreatment or large intermediate groups needing gene expression profiling. The machine learning model achieved AUC under ROC of 0.77 in training and 0.83 in validation cohorts for prediction of indication for adjuvant chemotherapy according to ROR/Prosigna. By setting and validating upper and lower cut-offs corresponding to low, intermediate and high-risk disease, we improved risk stratification accuracy and reduced the proportion of patients needing ROR/Prosigna testing compared to current risk stratification. Conclusion: Machine learning algorithms can enhance patient selection for gene expression profiling, though further external validation is needed.

Place, publisher, year, edition, pages
Elsevier, 2025
Keywords
Adjuvant, Breast cancer, Machine learning, Prosigna, Risk of recurrence
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-557864 (URN)10.1016/j.breast.2025.104489 (DOI)001492946000001 ()40347583 (PubMedID)2-s2.0-105004588252 (Scopus ID)
Funder
Swedish Cancer SocietySwedish Research Council
Available from: 2025-06-03 Created: 2025-06-03 Last updated: 2025-06-03Bibliographically approved
Herre, M., Vemuri, K., Cedervall, J., Nissl, S., Saupe, F., Micallef, J., . . . Olsson, A.-K. (2024). AAV-mouse DNase I sustains long-term DNase I expression in vivo and suppresses breast cancer metastasis. FASEB Bioadvances, 6(10), 454-466
Open this publication in new window or tab >>AAV-mouse DNase I sustains long-term DNase I expression in vivo and suppresses breast cancer metastasis
Show others...
2024 (English)In: FASEB Bioadvances, E-ISSN 2573-9832, Vol. 6, no 10, p. 454-466Article in journal (Refereed) Published
Abstract [en]

Neutrophil extracellular traps (NETs) have been implicated in the pathology of various inflammatory conditions. In cancer, NETs have been demonstrated to induce systemic inflammation, impair peripheral vessel and organ function and promote metastasis. Here we show that the plasma level of NETs is significantly higher in patients with metastatic breast cancer compared to those with local disease, or those that were considered cured at a 5-year follow-up, confirming NETs as interesting therapeutic targets in metastatic breast cancer. Administration of DNase I is one strategy to eliminate NETs but long-term treatment requires repeated injections and species-specific versions of the enzyme. To enhance administration and therapeutic efficacy, we have developed an adeno-associated virus (AAV) vector system for delivery of murine DNase I and addressed its potential to counteract cancer-associated pathology in the murine MMTV-PyMT model for metastatic mammary carcinoma. The AAV vector is comprised of capsid KP1 and an expression cassette encoding hyperactive murine DNase I (AAV-mDNase I) under the control of a liver-specific promotor. This AAV-mDNase I vector could support elevated expression and serum activity of murine DNase I over at least 8 months. Neutrophil Gelatinase-Associated Lipocalin (NGAL), a biomarker for kidney hypoperfusion that is upregulated in urine from MMTV-PyMT mice, was suppressed in mice receiving AAV-mDNase I compared to an AAV-null control group. Furthermore, the proportion of mice that developed lung metastasis was reduced in the AAV-mDNase I group. Altogether, our data indicate that AAV-mDNase I has the potential to reduce cancer-associated impairment of renal function and development of metastasis. We conclude that AAV-mDNase I could represent a promising therapeutic strategy in metastatic breast cancer.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:uu:diva-508007 (URN)10.1096/fba.2024-00114 (DOI)001303998900001 ()39372124 (PubMedID)2-s2.0-85202846255 (Scopus ID)
Funder
Swedish Cancer Society, 201283 PjFSwedish Research Council, 2023-02904
Available from: 2023-08-13 Created: 2023-08-13 Last updated: 2025-01-20Bibliographically approved
Vikmoen, O., Strandberg, E., Vassbakk Svindland, K., Henriksson, A., Mazzoni, A.-S., Johansson, B., . . . Raastad, T. (2024). Effects of heavy-load strength training during (neo-)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer. The FASEB Journal, 38(13), Article ID e23784.
Open this publication in new window or tab >>Effects of heavy-load strength training during (neo-)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer
Show others...
2024 (English)In: The FASEB Journal, ISSN 0892-6638, E-ISSN 1530-6860, Vol. 38, no 13, article id e23784Article in journal (Refereed) Published
Abstract [en]

To investigate the effects of heavy-load strength training during (neo-)adjuvant chemotherapy in women with breast cancer on muscle strength, body composition, muscle fiber size, satellite cells, and myonuclei. Women with stage I-III breast cancer were randomly assigned to a strength training group (ST, n = 23) performing supervised heavy-load strength training twice a week during chemotherapy, or a usual care control group (CON, n = 17). Muscle strength and body composition were measured and biopsies from m. vastus lateralis collected before the first cycle of chemotherapy (T0) and after chemotherapy and training (T1). Muscle strength increased significantly more in ST than in CON in chest-press (ST: +10 +/- 8%, p < .001, CON: -3 +/- 5%, p = .023) and leg-press (ST: +11 +/- 8%, p < .001, CON: +3 +/- 6%, p = .137). Both groups reduced fat-free mass (ST: -4.9 +/- 4.0%, p < .001, CON: -5.2 +/- 4.9%, p = .004), and increased fat mass (ST: +15.3 +/- 16.5%, p < .001, CON: +16.3 +/- 19.8%, p = .015) with no significant differences between groups. No significant changes from T0 to T1 and no significant differences between groups were observed in muscle fiber size. For myonuclei per fiber a non-statistically significant increase in CON and a non-statistically significant decrease in ST in type I fibers tended (p = .053) to be different between groups. Satellite cells tended to decrease in ST (type I: -14 +/- 36%, p = .097, type II: -9 +/- 55%, p = .084), with no changes in CON and no differences between groups. Strength training during chemotherapy improved muscle strength but did not significantly affect body composition, muscle fiber size, numbers of satellite cells, and myonuclei compared to usual care.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
body composition, breast neoplasms, drug therapy, exercise, muscle cells, resistance training
National Category
Sport and Fitness Sciences Physiology and Anatomy
Identifiers
urn:nbn:se:uu:diva-534964 (URN)10.1096/fj.202400634R (DOI)001260723100001 ()38953567 (PubMedID)
Funder
Swedish Cancer Society, 18 0356
Available from: 2024-07-12 Created: 2024-07-12 Last updated: 2025-02-11Bibliographically approved
Valachis, A., Biganzoli, L., Christopoulou, A., Fjermeros, K., Fountzila, E., Geisler, J., . . . Kosmidis, T. (2024). Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients. Future Oncology, 20(37), 2937-2948
Open this publication in new window or tab >>Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
Show others...
2024 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301, Vol. 20, no 37, p. 2937-2948Article in journal (Refereed) Published
Abstract [en]

Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (>= 70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment.

Place, publisher, year, edition, pages
Taylor & Francis, 2024
Keywords
advanced breast cancer, CDK4/6 inhibitors, comprehensive geriatric assessment, lower dose, randomized
National Category
Cancer and Oncology Geriatrics
Identifiers
urn:nbn:se:uu:diva-548565 (URN)10.1080/14796694.2024.2413841 (DOI)001337572800001 ()39431459 (PubMedID)2-s2.0-85207255072 (Scopus ID)
Funder
EU, Horizon Europe, 101104589
Available from: 2025-01-27 Created: 2025-01-27 Last updated: 2025-01-27Bibliographically approved
Valachis, A. & Lindman, H. (2024). Lessons learned from an unsuccessful decentralized clinical trial in Oncology. npj Digital Medicine, 7(1), Article ID 211.
Open this publication in new window or tab >>Lessons learned from an unsuccessful decentralized clinical trial in Oncology
2024 (English)In: npj Digital Medicine, E-ISSN 2398-6352, Vol. 7, no 1, article id 211Article in journal (Refereed) Published
Abstract [en]

Decentralized clinical trials have gained in popularity over the last years due to their advantages related to broadening recruitment strategies and resource saving possibilities. As more clinical trials adopt decentralized strategies, it is essential to share the knowledge about both successful and unsuccessful efforts in the research community. In the present commentary, we explore potential reasons that led to early termination of a decentralized clinical trial in Oncology.

Place, publisher, year, edition, pages
Springer Nature, 2024
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-537098 (URN)10.1038/s41746-024-01214-5 (DOI)001290252700002 ()39138304 (PubMedID)
Available from: 2024-08-27 Created: 2024-08-27 Last updated: 2024-08-27Bibliographically approved
Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., . . . Lindman, H. (2024). Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial. JAMA Network Open, 7(8), Article ID e2429772.
Open this publication in new window or tab >>Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial
Show others...
2024 (English)In: JAMA Network Open, E-ISSN 2574-3805, Vol. 7, no 8, article id e2429772Article in journal (Refereed) Published
Abstract [en]

Importance: The standard adjuvant treatment for patients with ERRB2-positive breast cancer is chemotherapy plus 1 year of trastuzumab. Shorter durations of trastuzumab administration improve cardiac safety, but more information is needed about their effect on survival.

Objective: To compare survival outcomes after 9-week vs 1-year administration of trastuzumab with the same adjuvant chemotherapy.

Design, Setting, and Participants: This post hoc secondary analysis of an open-label, multicenter, noninferiority-design randomized clinical trial included women aged 18 years or older with early ERBB2-positive, axillary node-negative or axillary node-positive breast cancer who were enrolled from January 3, 2008, to December 16, 2014, at 65 centers in 7 European countries. The current exploratory analysis was conducted after achieving the maximum attainable follow-up data when the last patient enrolled had completed the last scheduled visit in December 2022.

Intervention: Chemotherapy consisted of 3 cycles of docetaxel administered at 3-week intervals followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide at 3-week intervals. Trastuzumab was administered in both groups for 9 weeks concomitantly with docetaxel. In the 9-week group, no further trastuzumab was administered after chemotherapy, whereas in the 1-year group, trastuzumab was continued after chemotherapy to complete 1 year of administration.

Main Outcomes and Measures: The primary objective was disease-free survival (DFS). Distant DFS and OS were secondary objectives. Survival between groups was compared using the Kaplan-Meier method and log-rank test or univariable Cox proportional hazards regression.

Results: Among the 2174 women analyzed, median age was 56 years (IQR, 48-64 years). The median follow-up time was 8.1 years (IQR, 8.0-8.9 years); 357 DFS events and 176 deaths occurred. Trastuzumab for 9 weeks was associated with shorter DFS compared with trastuzumab for 1 year (hazard ratio [HR], 1.36; 90% CI, 1.14-1.62); 10-year DFS was 80.3% in the 1-year group vs 78.6% in the 9-week group. The 5-year and 10-year OS rates were comparable between the 9-week and 1-year groups (95.0% vs 95.9% and 89.1% vs 88.2%, respectively; HR for all time points, 1.20; 90% CI, 0.94-1.54). In multivariable analyses, 9-week treatment was associated with shorter DFS compared with 1-year treatment (HR for recurrence or death, 1.36; 95% CI, 1.10-1.68; P = .005), but there was no between-group difference in OS (HR, 1.22; 95% CI, 0.90-1.64; P = .20). Only 4 patients (0.2%) died of a cardiac cause. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, 1-year vs 9-week adjuvant trastuzumab was associated with improved DFS among patients with ERRB2-positive breast cancer receiving chemotherapy, but there was no significant difference in OS between the groups.

Trial Registration ClinicalTrials.gov Identifier: NCT00593697

Place, publisher, year, edition, pages
American Medical Association (AMA), 2024
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-538969 (URN)10.1001/jamanetworkopen.2024.29772 (DOI)001302998700009 ()39186271 (PubMedID)2-s2.0-85202267217 (Scopus ID)
Available from: 2024-10-07 Created: 2024-10-07 Last updated: 2024-12-03Bibliographically approved
Zhu, Y., Zerdes, I., Matikas, A., Cruz, I. R., Bergqvist, M., Elinder, E., . . . Foukakis, T. (2024). The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial. Breast Cancer Research and Treatment, 204(2), 299-308
Open this publication in new window or tab >>The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Show others...
2024 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 204, no 2, p. 299-308Article in journal (Refereed) Published
Abstract [en]

Background

Thymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and as an early indicator of treatment response in human epidermal growth factor 2 (HER2)-negative early and metastatic breast cancer (BC). However, the prognostic and predictive value of serial TK1 activity in HER2-positive BC remains unknown.

Methods

In the PREDIX HER2 trial, 197 HER2-positive BC patients were randomized to neoadjuvant trastuzumab, pertuzumab, and docetaxel (DPH) or trastuzumab emtansine (T-DM1), followed by surgery and adjuvant epirubicin and cyclophosphamide. Serum samples were prospectively collected from all participants at multiple timepoints: at baseline, after cycle 1, 2, 4, and 6, at end of adjuvant therapy, annually for a total period of 5 years and/or at the time of recurrence. The associations of sTK1 activity with baseline characteristics, pathologic complete response (pCR), event-free survival (EFS), and disease-free survival (DFS) were evaluated.

Results

No association was detected between baseline sTK1 levels and all the baseline clinicopathologic characteristics. An increase of TK1 activity from baseline to cycle 2 was seen in all cases. sTK1 level at baseline, after 2 and 4 cycles was not associated with pCR status. After a median follow-up of 58 months, 23 patients had EFS events. There was no significant effect between baseline or cycle 2 sTK1 activity and time to event. A non-significant trend was noted among patents with residual disease (non-pCR) and high sTK1 activity at the end of treatment visit, indicating a potentially worse long-term prognosis.

Conclusions

TK1 activity increased following neoadjuvant therapy for HER2-positive BC but was not associated with patient outcomes or treatment benefit. However, the post-surgery prognostic value in patients that have not attained pCR warrants further investigation.

Trial registration

ClinicalTrials.gov, NCT02568839. Registered on 6 October 2015.

Place, publisher, year, edition, pages
Springer, 2024
Keywords
Thymidine kinase, HER2+breast cancer, Biomarker, Neoadjuvant treatment, Prognosis
National Category
Cancer and Oncology Medical Bioscience
Identifiers
urn:nbn:se:uu:diva-531491 (URN)10.1007/s10549-023-07200-x (DOI)001135975300001 ()38175448 (PubMedID)
Funder
Swedish Cancer SocietySwedish Research CouncilThe Cancer Society in StockholmThe Breast Cancer FoundationSwedish Cancer SocietyRegion StockholmIris, Stig och Gerry Castenbäcks Stiftelse för CancerforskningThe Cancer Research Funds of RadiumhemmetKnut and Alice Wallenberg Foundation
Available from: 2024-06-18 Created: 2024-06-18 Last updated: 2024-06-18Bibliographically approved
Palmer, S., Blomqvist, C., Holmqvist, M., Lindman, H., Lambe, M. & Ahlgren, J. (2024). Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry. BMC Cancer, 24(1), Article ID 329.
Open this publication in new window or tab >>Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry
Show others...
2024 (English)In: BMC Cancer, E-ISSN 1471-2407, Vol. 24, no 1, article id 329Article in journal (Refereed) Published
Abstract [en]

Background: Population-based cancer quality registries are of great importance for the improvement of cancer care. However, little is known about the quality of recurrence data in cancer quality registries. The aim of this study was to evaluate data quality in the regional Breast Cancer Quality Registry of Central Sweden, with emphasis on the validity of recorded information on recurrence.

Methods: Validation by re-abstraction was performed on a random sample of 800 women with primary invasive breast cancer stage I-III diagnosed between 1993 and 2010, of which 400 had at least one registered recurrence and 400 had no registered recurrence. Registry data were compared with data from medical records. Exact agreement, correlation and kappa values, sensitivity and specificity were calculated.

Results: Seven hundred forty-seven women (93%) were available for analysis. Exact agreement was high for diagnostics, tumor characteristics, surgery, and adjuvant oncological treatment (90% or more for most variables). The registry's sensitivity was low for regional recurrence (47%), but higher for local and distant recurrence (80% and 75%), whereas specificity was overall high (>= 95%). Combining all recurrence categories irrespective of localization improved sensitivity to 90% with a specificity of 91%. In 87% of women, the date of first recurrence according to medical records fell within +/- 90 days of the date recorded in the registry.

Conclusions: While the quality of data in the regional Breast Cancer Quality Registry was generally high, data accuracy on recurrences was lower. The overall precision of identifying any recurrence, irrespective of localization, was high. However, the accuracy of classification of recurrences (local, regional or distant) was lower, with evidence of underreporting for each of the recurrence categories. Given the importance of recurrence-related outcomes in the assessment of quality of care, efforts should be made to improve the reporting of recurrences.

Place, publisher, year, edition, pages
Springer Nature, 2024
Keywords
Breast cancer, Quality registry, Validation, Data accuracy, Follow-up studies
National Category
Cancer and Oncology Surgery
Identifiers
urn:nbn:se:uu:diva-525479 (URN)10.1186/s12885-024-12073-4 (DOI)001182390800002 ()38468209 (PubMedID)
Available from: 2024-03-25 Created: 2024-03-25 Last updated: 2024-07-04Bibliographically approved
Nordenskjöld, A., Fohlin, H., Rosell, J., Bengtsson, N.-O., Fornander, T., Hatschek, T., . . . Nordenskjöld, B. (2023). Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. Breast, 71, 63-68
Open this publication in new window or tab >>Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
Show others...
2023 (English)In: Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 71, p. 63-68Article in journal (Refereed) Published
Abstract [en]

Background

Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated.

Material and methods

We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of adjuvant tamoxifen.

Results

After 5 years of follow-up, when tamoxifen treatment was finished in both groups, until 15 years of follow-up, overall mortality (HR 0.80, 95% CI 0.72–0.90, p < 0.001), breast cancer mortality for all patients (HR 0.80, 95% CI 0.68–0.94, p = 0.006) and breast cancer mortality for patients with estrogen receptor positive disease (HR 0.67, 95% CI 0.55–0.83, p < 0.001) were significantly reduced in the five-year group as compared to the two-year group. After 15 years, the difference remained but did not further increase.

In the five-year group, the incidence of contralateral breast cancer was gradually reduced during the entire period of observation. The incidence of lung cancer was also reduced in the five-year group. In contrast there was an increased endometrial cancer incidence in the five-year group and for those receiving 40 mg of tamoxifen this incidence was further increased.

Conclusion

Three more years of tamoxifen therapy reduced the risk of breast cancer mortality. The difference was established during the first 15 years after randomization. Moreover, the incidence of contralateral breast cancer gradually decreased for 30 years. The incidence of lung cancer was reduced in the five-year group. In contrast the incidence of endometrial cancer was increased.

Place, publisher, year, edition, pages
Elsevier, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-520014 (URN)10.1016/j.breast.2023.07.010 (DOI)001060449900001 ()37517154 (PubMedID)
Funder
Swedish Cancer SocietyKing Gustaf V Jubilee FundThe Breast Cancer Foundation
Available from: 2024-01-25 Created: 2024-01-25 Last updated: 2024-01-25Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-5871-268x

Search in DiVA

Show all publications